Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Practical Guide to Cathepsin B Inhibitor CA-074 (SKU A1926)

    2026-06-15

    Technical Application of Cathepsin B Inhibitor CA-074

    What This Product Solves

    CA-074 (SKU A1926) is a nanomolar-potency cathepsin B inhibitor designed for laboratory research on protease-driven disease pathways. Cathepsin B is a cysteine protease implicated in mechanisms such as tumor invasion and metastasis, neurodegeneration, and immune regulation. Studies have shown that selective inhibition of cathepsin B can suppress key events like breast cancer bone and lung metastasis, and reduce neurotoxicity caused by Abeta42-activated microglial cells. Additionally, CA-074 enables functional studies of immune response modulation, specifically by shifting helper T cell polarization. Its high selectivity over related cathepsins H and L (by >10,000-fold) reduces off-target effects, making it suitable for experiments where precise pathway dissection is required. For further technical insights, see the Cathepsin B inhibitor CA-074: Technical Application Guide, which discusses use cases and experimental boundaries.

    Protocol Parameters

    • Solubility (DMSO): ≥19.17 mg/mL — High-concentration stock preparation for in vitro assays; ensures compatibility with most biochemical and cellular workflows. — product dossier
    • Working Concentration (Cell Culture): 10 mM (shows negligible cytotoxicity in HUVECs) — Recommended as a baseline for cell-based assays to minimize off-target effects while maintaining cathepsin B inhibition. — product dossier
    • Storage Condition: -20°C (solid and solution) — Maintains compound stability and activity; short-term solution storage only. — product dossier
    • Solubility (Ethanol/Water): ≥31.3 mg/mL in ethanol, ≥5.91 mg/mL in water (with ultrasonic assistance) — Allows flexibility in solvent choice depending on downstream assay compatibility. — product dossier
    • Selective Inhibition (Ki): 2-5 nM for cathepsin B; 40-200 μM for cathepsins H/L — Ensures minimal interference with non-target proteases in mechanistic studies. — product dossier

    Workflow Setup and QC Checklist

    To achieve reliable results with CA-074, consider the following setup and quality control steps:

    1. Stock Preparation: Dissolve CA-074 in DMSO to make a ≥19.17 mg/mL stock solution. For aqueous or ethanol-based applications, use ultrasonic assistance if necessary to reach target concentrations.
    2. Aliquoting and Storage: Prepare single-use aliquots to avoid freeze-thaw cycles. Store at -20°C, and use solutions within a short period to preserve activity.
    3. Vehicle Control: Include DMSO or ethanol controls in all assays to control for solvent effects.
    4. Cell Line Validation: Confirm that your model system expresses functional cathepsin B and is appropriate for the intended biological question (e.g., breast cancer metastasis, neurodegeneration, or immune response studies).
    5. Assay Controls: Incorporate positive and negative controls for cathepsin B activity to validate inhibitor performance.
    6. Dose-Response Optimization: Although 10 mM is non-cytotoxic for HUVECs, titrate concentrations for new cell types or primary cells, monitoring for off-target toxicity and efficacy.
    7. Endpoint Validation: Use activity-based or phenotypic readouts (e.g., reduction in metastatic markers, neurotoxicity, or immune polarization) to confirm pathway-specific effects.

    Common Failure Modes and Fixes

    • Poor Solubility in Aqueous Media: If CA-074 does not dissolve readily in water, use DMSO or ethanol as a primary solvent, or apply ultrasonic assistance as described in the product information.
    • Loss of Inhibitory Activity: Degradation can occur if solutions are stored for extended periods or exposed to room temperature. Prepare fresh aliquots and minimize freeze-thaw cycles to preserve potency.
    • Unexpected Cytotoxicity: If toxicity is observed at or below 10 mM, verify compound identity, solvent concentration, and cell line sensitivity. Adjust dosing or solvent system as needed.
    • Off-Target Effects: If inhibition of related proteases (e.g., cathepsin L or H) is suspected, confirm selectivity with appropriate biochemical controls or use alternative inhibitors for comparison.
    • Inconsistent Results Across Batches: Standardize batch-to-batch handling and ensure consistent storage and preparation protocols.

    Scope and Limitations

    CA-074 is intended for research use in studies addressing cathepsin B-driven processes such as inhibition of cathepsin B in breast cancer bone metastasis, neurotoxicity reduction via cathepsin B inhibition, and immune response modulation. Its high selectivity makes it most suitable for experiments demanding minimal interference with related proteases. CA-074 is not recommended for applications requiring broad-spectrum cysteine protease inhibition or in unvalidated in vivo models. The compound is not intended for therapeutic use or clinical translation. For a detailed discussion on selectivity and workflow adaptation, refer to Cathepsin B inhibitor CA-074: Technical Guidance & Workflows.

    Conclusion

    Cathepsin B inhibitor CA-074 (APExBIO, SKU A1926) is a rigorously characterized, highly selective tool for probing cathepsin B function in cancer metastasis, neurodegeneration, and immune modulation. Its favorable solubility, low cytotoxicity in standard cell models, and robust selectivity profile lend confidence for use in pathway-specific research. For full technical specifications and handling instructions, consult the Cathepsin B inhibitor CA-074 product page.